Zobrazeno 1 - 10
of 142 580
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Garth W. Strohbehn, Robert Holleman, Jennifer Burns, Mandi L. Klamerus, Michael J. Kelley, Eve A. Kerr, Nithya Ramnath, Timothy P. Hofer
Publikováno v:
JAMA oncology. 8(11)
ImportanceExtended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance
Autor:
Judith E. Carroll, Zev M. Nakamura, Brent J. Small, Xingtao Zhou, Harvey J. Cohen, Tim A. Ahles, Jaeil Ahn, Traci N. Bethea, Martine Extermann, Deena Graham, Claudine Isaacs, Heather S.L. Jim, Paul B. Jacobsen, Brenna C. McDonald, Sunita K. Patel, Kelly Rentscher, James Root, Andrew J. Saykin, Danielle B. Tometich, Kathleen Van Dyk, Wanting Zhai, Elizabeth C. Breen, Jeanne S. Mandelblatt
Publikováno v:
Journal of Clinical Oncology. 41:295-306
PURPOSE To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors and noncancer controls. METHODS English-speaking women age ≥ 60 years, newly diagnosed with primary breast cance
Autor:
Birgitte V, Offersen, Jan, Alsner, Hanne M, Nielsen, Erik H, Jakobsen, Mette H, Nielsen, Lars, Stenbygaard, Anders N, Pedersen, Mette S, Thomsen, Esben, Yates, Martin, Berg, Ebbe L, Lorenzen, Ingelise, Jensen, Mirjana, Josipovic, Maj-Britt, Jensen, Jens, Overgaard
Publikováno v:
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Stenbygaard, L, Pedersen, A N, Thomsen, M S, Yates, E, Berg, M, Lorenzen, E L, Jensen, I, Josipovic, M, Jensen, M-B, Overgaard, J & Danish Breast Cancer Group Radiotherapy Committee 2022, ' Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial : The Danish Breast Cancer Group Partial Breast Irradiation Trial ', Journal of Clinical Oncology, vol. 40, no. 36, JCO2200451, pp. 4189-4197 . https://doi.org/10.1200/JCO.22.00451
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Stenbygaard, L, Pedersen, A N, Thomsen, M S, Yates, E, Berg, M, Lorenzen, E L, Jensen, I, Josipovic, M, Jensen, M B, Overgaard, J & Danish Breast Cancer Group Radiotherapy Committee 2022, ' Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial : The Danish Breast Cancer Group Partial Breast Irradiation Trial ', Journal of Clinical Oncology, vol. 40, no. 36, pp. 4189-4197 . https://doi.org/10.1200/JCO.22.00451
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Stenbygaard, L, Pedersen, A N, Thomsen, M S, Yates, E, Berg, M, Lorenzen, E L, Jensen, I, Josipovic, M, Jensen, M B, Overgaard, J & Danish Breast Cancer Group Radiotherapy Committee 2022, ' Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial : The Danish Breast Cancer Group Partial Breast Irradiation Trial ', Journal of Clinical Oncology, vol. 40, no. 36, pp. 4189-4197 . https://doi.org/10.1200/JCO.22.00451
PURPOSE On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation (WBI), the Danish Breast Cancer Group initiated the noninferiority external-beam partial breas
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity